What is Zacks Research's Estimate for IRWD Q4 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Research analysts at Zacks Research upped their Q4 2025 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $0.16 per share for the quarter, up from their prior forecast of $0.12. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.34 EPS and Q1 2027 earnings at $0.02 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). The firm had revenue of $41.14 million during the quarter, compared to analysts' expectations of $67.02 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.

A number of other research firms also recently commented on IRWD. Wells Fargo & Company reiterated an "equal weight" rating and issued a $1.00 target price (down from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Citizens Jmp lowered shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 14th. Leerink Partners decreased their price objective on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Craig Hallum downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Finally, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Seven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Ironwood Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $4.78.

Ironwood Pharmaceuticals Trading Down 3.4%

Shares of NASDAQ:IRWD traded down $0.02 during mid-day trading on Friday, reaching $0.60. The stock had a trading volume of 833,206 shares, compared to its average volume of 2,579,701. The company has a market cap of $97.25 million, a P/E ratio of -20.03 and a beta of 0.37. Ironwood Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $7.11. The business's 50 day moving average price is $0.87 and its 200 day moving average price is $2.23.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently bought and sold shares of IRWD. Armistice Capital LLC boosted its position in Ironwood Pharmaceuticals by 44.7% in the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock valued at $20,139,000 after buying an additional 4,232,000 shares during the last quarter. Millennium Management LLC boosted its position in Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock worth $9,349,000 after purchasing an additional 4,140,439 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Ironwood Pharmaceuticals by 740.5% during the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company's stock valued at $5,160,000 after buying an additional 3,092,475 shares in the last quarter. AQR Capital Management LLC raised its stake in Ironwood Pharmaceuticals by 535.8% in the 1st quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company's stock valued at $3,710,000 after purchasing an additional 2,126,889 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in Ironwood Pharmaceuticals by 160.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company's stock valued at $3,878,000 after purchasing an additional 1,630,726 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.